A Study of Selumetinib in Patients With Kaposi's Sarcoma

Inclusion Criteria: * Histologically confirmed KS. * Measurable disease according to ACTG criteria. * Evidence of disease progression in the past 6 months. No anti-cancer treatment within one month prior to commencing trial treatment. * Progressive cutaneous or nodal KS not requiring chemotherapy OR progressive KS following cytotoxic chemotherapy. * Adequate haematological function: * Haemoglobin ≥ 9 g/dL * Absolute neutrophil count ≥ 1.5 x 10 9/L * Platelets ≥ 100 x 10 9/L * Adequate hepatic function: * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN), except if the patient is established on the anti-retroviral drug atazanavir (no upper limit) and has aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 x ULN * ALT ≤ 2.5 x ULN * AST ≤ 2.5 x ULN * Adequate renal function: * Serum creatinine clearance \> 50 ml/min (Cockcroft-Gault formula or 24 hour urine collection). * Left ventricular function \>50% normal * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * For selumetinib, women of child bearing age and child bearing potential MUST have a negative pregnancy test prior to study entry AND be using an adequate contraception method, which must be continued while on treatment and for at least 4 weeks after the study treatment has ended. * Male patients must agree to use an effective contraception method while on treatment and for at least 16 weeks after the study treatment has ended (barrier con…